## **RESPIRATORY VIRUS DETECTIONS AND BACTERIAL INFECTIONS AMONG NON-HOSPITALIZED CHILDREN** WITH COMMUNITY-ACQUIRED PNEUMONIA TREATED WITH AMOXICILLIN: A PROSPECTIVE COHORT

Cristiana M. Nascimento-Carvalho<sup>1,2</sup>, Amanda C. Nascimento-Carvalho<sup>3</sup>, Ana-Luisa Vilas-Boas<sup>2</sup>, Maria-Socorro H. Fontoura<sup>1</sup>, Dafne C. Andrade<sup>2</sup>, Igor C. Borges<sup>2</sup>, Aldina Barral<sup>2,4</sup>, Mirja Puolakkainen<sup>5,6</sup>, Maria Soderlund-Venermo<sup>6</sup>, Helena Käyhty<sup>7</sup>, Tytti Vuorinen<sup>8</sup>, Olli Ruuskanen<sup>9</sup>, and the PNEUMOPAC-Efficacy Study Group<sup>1</sup> Affiliations:

<sup>1</sup>Department of Paediatrics, Federal University of Bahia School of Medicine, Salvador, Brazil

<sup>2</sup>Postgraduate Programme in Health Sciences, Federal University of Bahia School of Medicine, Salvador, Bahia, Brazil <sup>3</sup>Bahiana School of Medicine, Bahiana Foundation for Science Development, Salvador, Brazil

<sup>4</sup>Pathology Department, Federal University of Bahia School of Medicine and Centro de Pesquisa Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil <sup>5</sup>Helsinki University Hospital, Helsinki, Finland

<sup>6</sup>Department of Virology, University of Helsinki, Helsinki, Finland

<sup>7</sup>National Institute for Health and Welfare, Helsinki, Finland

<sup>8</sup>Department of Clinical Virology, Turku University Hospital, and Department of Virology, Turku University, Turku, Finland <sup>9</sup>Department of Paediatrics, University of Turku, Turku, Finland

**Background:** Communityacquired pneumonia (CAP) imposes big morbidity and mortality in children and may by caused several be pathogens. Amoxicillin is the first-choice antibiotic to treat empirically non-hospitalized children with CAP.

Aims: We described the frequency of virus detections bacterial infections and in non-hospitalized children with CAP treated with amoxicillin and compared the amoxicillin substitution rate due to failure treatment among children with or without typical bacterial infection.

Funding:

Methods: Children aged 2-59 months with non-severe CAP (respiratory complaints plus radiographic pulmonary infiltrate/consolidation) were enrolled in a prospective cohort, in Salvador, Brazil.

From 820 patients recruited in clinical trial a (ClinicalTrials.gov Identifier NCT01200706), 705 (86.0%) had nasopharyngeal aspirates (NPA) and serum collected upon admission and serum collected 2-4 weeks apart. NPAs were tested for 16 respiratory viruses by PCRs and bacterial infections were serology. investigated by Follow-up assessments occurred at 2, 5, and 14 days after enrolment.

**Results:** Respiratory viruses were detected in 643 (91.2%) cases, typical atypical and infections bacterial being diagnosed in 166 (23.5%) and 141 (20.0%), respectively. Typical infections bacterial comprised pneumococcal (18.3%), Haemophilus influenzae (5.8%), and Moraxella catarrhalis (2.7%) infections. The majority of the cases (55.6%) had only virus detection. Amoxicillin was substituted in 4 (0.6%) and in 19 (2.7%) patients due to adverse failure, clinical event or respectively.













Turun yliopisto University of Turku

no significant There was difference when the amoxicillin substitution rate due to clinical failure was children compared among with without or typical bacterial infection (P=0.2):

Amoxicillin substitution	Typical bacterial infection		Total
due to failure	Yes	No	
Yes	7 (4.3%)	12 (2.2%)	19 (2.7%)
No	157	525	682
Total	164	537	701

**Conclusions:** Respiratory viruses were detected in almost all cases and typical bacterial infection found was in approximately one fourth of them. It is crucial to distinguish with from children children without typical bacterial infection in order to rationalize antibiotic use.

E-mail: nascimentocarvalho@hotmail.com (C. M. Nascimento-Carvalho)

This work was supported by a grant from the Bahia State Agency for Research Funding (FAPESB) (Grant No. PPSUS Nº.

SUS0023/2013) as well as by the Helsinki University 375-year grant, the Sigrid Jusélius Foundation and the Chinese Scholarship Council. CMN-C is senior investigator at the Brazilian Council for Scientific and Technological Development (CNPq).